252 related articles for article (PubMed ID: 15452682)
1. Paroxetine combined with a 5-HT(1A) receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats.
Markou A; Harrison AA; Chevrette J; Hoyer D
Psychopharmacology (Berl); 2005 Mar; 178(2-3):133-42. PubMed ID: 15452682
[TBL] [Abstract][Full Text] [Related]
2. Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats.
Harrison AA; Liem YT; Markou A
Neuropsychopharmacology; 2001 Jul; 25(1):55-71. PubMed ID: 11377919
[TBL] [Abstract][Full Text] [Related]
3. Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: involvement of serotonin-1A receptors.
Harrison AA; Markou A
J Pharmacol Exp Ther; 2001 Apr; 297(1):316-25. PubMed ID: 11259559
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat--interactions between the two drugs.
Lin D; Koob GF; Markou A
Psychopharmacology (Berl); 1999 Aug; 145(3):283-94. PubMed ID: 10494577
[TBL] [Abstract][Full Text] [Related]
5. Effect of different 5-HT1A receptor antagonists in combination with paroxetine on expression of the immediate-early gene Arc in rat brain.
Tordera R; Pei Q; Newson M; Gray K; Sprakes M; Sharp T
Neuropharmacology; 2003 Jun; 44(7):893-902. PubMed ID: 12726821
[TBL] [Abstract][Full Text] [Related]
6. Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain.
Besson A; Haddjeri N; Blier P; de Montigny C
Eur Neuropsychopharmacol; 2000 May; 10(3):177-88. PubMed ID: 10793320
[TBL] [Abstract][Full Text] [Related]
7. Effects of repeated withdrawal from continuous amphetamine administration on brain reward function in rats.
Paterson NE; Myers C; Markou A
Psychopharmacology (Berl); 2000 Nov; 152(4):440-6. PubMed ID: 11140337
[TBL] [Abstract][Full Text] [Related]
8. 5-HT(1A) receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats.
Sukoff Rizzo SJ; Pulicicchio C; Malberg JE; Andree TH; Stack GP; Hughes ZA; Schechter LE; Rosenzweig-Lipson S
Int J Neuropsychopharmacol; 2009 Sep; 12(8):1045-53. PubMed ID: 19435548
[TBL] [Abstract][Full Text] [Related]
9. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
Hughes ZA; Starr KR; Langmead CJ; Hill M; Bartoszyk GD; Hagan JJ; Middlemiss DN; Dawson LA
Eur J Pharmacol; 2005 Mar; 510(1-2):49-57. PubMed ID: 15740724
[TBL] [Abstract][Full Text] [Related]
10. Serotonin-1A receptors in the dorsal periaqueductal gray matter mediate the panicolytic-like effect of pindolol and paroxetine combination in the elevated T-maze.
Sela VR; Biesdorf C; Ramos DH; Zangrossi H; Graeff FG; Audi EA
Neurosci Lett; 2011 May; 495(1):63-6. PubMed ID: 21421022
[TBL] [Abstract][Full Text] [Related]
11. Effects of the potential antidepressant OPC-14523 [1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2-quinolinone monomethanesulfonate] a combined sigma and 5-HT1A ligand: modulation of neuronal activity in the dorsal raphe nucleus.
Bermack JE; Haddjeri N; Debonnel G
J Pharmacol Exp Ther; 2004 Aug; 310(2):578-83. PubMed ID: 15044555
[TBL] [Abstract][Full Text] [Related]
12. Psychopharmacological profile of the selective serotonin reuptake inhibitor, paroxetine: implication of noradrenergic and serotonergic mechanisms.
Redrobe JP; Bourin M; Colombel MC; Baker GB
J Psychopharmacol; 1998; 12(4):348-55. PubMed ID: 10065908
[TBL] [Abstract][Full Text] [Related]
13. Effect of a selective 5-HT reuptake inhibitor in combination with 5-HT1A and 5-HT1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo.
Sharp T; Umbers V; Gartside SE
Br J Pharmacol; 1997 Jul; 121(5):941-6. PubMed ID: 9222551
[TBL] [Abstract][Full Text] [Related]
14. Use of Arc expression as a molecular marker of increased postsynaptic 5-HT function after SSRI/5-HT1A receptor antagonist co-administration.
Castro E; Tordera RM; Hughes ZA; Pei Q; Sharp T
J Neurochem; 2003 Jun; 85(6):1480-7. PubMed ID: 12787067
[TBL] [Abstract][Full Text] [Related]
15. Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition.
Jones CK; Eastwood BJ; Need AB; Shannon HE
Neuropharmacology; 2006 Dec; 51(7-8):1172-80. PubMed ID: 17045620
[TBL] [Abstract][Full Text] [Related]
16. Serotonin in the ventral hippocampus modulates anxiety-like behavior during amphetamine withdrawal.
Tu W; Cook A; Scholl JL; Mears M; Watt MJ; Renner KJ; Forster GL
Neuroscience; 2014 Dec; 281():35-43. PubMed ID: 25241066
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of hippocampal 5-HT synthesis by fluoxetine and paroxetine: evidence for the involvement of both 5-HT1A and 5-HT1B/D autoreceptors.
Barton CL; Hutson PH
Synapse; 1999 Jan; 31(1):13-9. PubMed ID: 10025679
[TBL] [Abstract][Full Text] [Related]
18. S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine.
Millan MJ; Dekeyne A; Gobert A; Mannoury la Cour C; Brocco M; Rivet JM; Di Cara B; Lejeune F; Cremers TI; Flik G; de Jong TR; Olivier B; de Nanteuil G
Eur Neuropsychopharmacol; 2010 Sep; 20(9):599-621. PubMed ID: 20483567
[TBL] [Abstract][Full Text] [Related]
19. SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test.
Starr KR; Price GW; Watson JM; Atkinson PJ; Arban R; Melotto S; Dawson LA; Hagan JJ; Upton N; Duxon MS
Neuropsychopharmacology; 2007 Oct; 32(10):2163-72. PubMed ID: 17356576
[TBL] [Abstract][Full Text] [Related]
20. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat.
Cryan JF; Bruijnzeel AW; Skjei KL; Markou A
Psychopharmacology (Berl); 2003 Jul; 168(3):347-58. PubMed ID: 12698231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
